Fulltext

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial†

Klingbiel, D. ; Saridaki, Z. ; Roth, A. D. ; Bosman, F. T. ; Delorenzi, M. ; Tejpar, S.

In: Annals of Oncology, 2015, vol. 26, no. 1, p. 126-132

Ajouter à la liste personnelle
    Titre
    • Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial†
    Auteur
    • Klingbiel, D.. SAKK Swiss Group for Clinical Cancer Research, Coordinating Center, Bern
    • Saridaki, Z.. Laboratory of Tumor Cell Biology School of Medicine, University of Crete, Heraklion, Greece
    • Roth, A. D.. Oncosurgery Unit, Geneva University Hospital, Geneva
    • Bosman, F. T.. Department of Pathology, Lausanne University, Lausanne
    • Delorenzi, M.. SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
    • Tejpar, S.. Center for Human Genetics O&N1, Katholieke Universiteit Leuven, Leuven, Belgium
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2015, vol. 26, no. 1, p. 126-132. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:291587
    Summary
    We examined the effect of MSI status in a trial-based cohort of 1254 stage II and III colon cancer (CC) patients treated with 5-FU/LV or FOLFIRI. We confirm that for stage II CC MSI is strongly prognostic for RFS and OS. No significant differences were found between treatment arms. Adding irinotecan to 5-FU did not benefit MSI-H tumors. RFS was better for MSI-H CC both in the right and left colon